Floatz logo

iam1363

Brain Metastases From Solid Tumors

Iambic Therapeutics, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

102 Active assets in the Brain Metastases From Solid Tumors cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

iam1363 is also rated in:

HER2 positive breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
Brain Metastases From HER2 and Breast CancerDormant
CC
Indicative ·
43 / 100
View asset →
neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →